Literature DB >> 22678150

Prevalence, patterns of treatment, and control of hypertension in predialysis patients with chronic kidney disease.

Pantelis A Sarafidis1, Claire C Sharpe, Eleri Wood, Rochelle Blacklock, Adam Rumjon, Aziza Al-Yassin, Rachel Ariyanayagam, Shanique Simmonds, Jessica Fletcher-Rogers, Katie Vinen.   

Abstract

BACKGROUND/AIMS: Data on the prevalence, treatment and control of hypertension in patients with advanced chronic kidney disease (CKD) are limited. This study aimed to examine the above factors in a cohort of predialysis patients.
METHODS: During a period of 4 months, we recorded information on blood pressure (BP), comorbidities, medications and related parameters of patients followed up in the Low-Clearance Clinic of our Department. Control rates of hypertension were calculated at two thresholds: <130/80 and <140/90 mm Hg. Univariate and multiple linear regression analyses were employed to assess factors associated with BP control.
RESULTS: In the population studied [n = 238, males 58.4%, age 66.21 ± 4.2 years (mean ± SD), estimated glomerular filtration rate 14.5 ± 4.8 ml/min/1.73 m(2)], the prevalence of hypertension was 95.0%. Treatment rate among hypertensives was at 99.1%. On average, 3.04 ± 1.32 antihypertensive drugs were used, ranging from 1 to 7 agents. BP control rates at the <130/80 and <140/90 mm Hg thresholds were 26.5% and 48.2%, respectively. The systolic goal was achieved in 31.0% and 50.4%, whereas the diastolic goal was achieved in 67.7% and 91.2% of patients, respectively. In multivariate analysis, only black race was independently and inversely related with hypertension control (β = -0.187, p = 0.030). No specific antihypertensive class showed independent associations with control.
CONCLUSIONS: Hypertension is highly prevalent in predialysis CKD patients. An almost universal treatment, employing a multi-agent regime, can help towards improved rates of control. Systolic BP is the main barrier to successful control and black race is associated with poorer control rates.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22678150     DOI: 10.1159/000337571

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  13 in total

1.  Prevalence of apparent treatment-resistant hypertension among individuals with CKD.

Authors:  Rikki M Tanner; David A Calhoun; Emmy K Bell; C Barrett Bowling; Orlando M Gutiérrez; Marguerite R Irvin; Daniel T Lackland; Suzanne Oparil; David Warnock; Paul Muntner
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

Review 2.  The optimal blood pressure target in diabetes mellitus: a quest coming to an end?

Authors:  Eirini Papadopoulou; Elena Angeloudi; Spiridon Karras; Pantelis Sarafidis
Journal:  J Hum Hypertens       Date:  2018-06-22       Impact factor: 3.012

3.  Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD.

Authors:  L-N Zhang; G Yang; C Cheng; C Shen; Y-Y Cui; J Zhang; J-J Zhang; Z-X Shen; M Zeng; Y-F Ge; B Sun; X-B Yu; C Ouyang; B Zhang; H-J Mao; J Liu; C-Y Xing; X-M Zha; N-N Wang
Journal:  Osteoporos Int       Date:  2014-09-16       Impact factor: 4.507

4.  Utilization of antihypertensive drugs among chronic kidney disease patients: Results from the Chinese cohort study of chronic kidney disease (C-STRIDE).

Authors:  Bianling Liu; Qin Wang; Yu Wang; Jinwei Wang; Luxia Zhang; Minghui Zhao
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-09       Impact factor: 3.738

5.  Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients.

Authors:  Marit M Suttorp; Tiny Hoekstra; Moshe Mittelman; Ilka Ott; Casper F M Franssen; Friedo W Dekker
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

6.  Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.

Authors:  Sadayoshi Ito; Minoru Satoh; Yuko Tamaki; Hiromi Gotou; Alan Charney; Naoko Okino; Mizuki Akahori; Jack Zhang
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

Review 7.  From ARB to ARNI in Cardiovascular Control.

Authors:  Estrellita Uijl; Lodi C W Roksnoer; Ewout J Hoorn; A H Jan Danser
Journal:  Curr Hypertens Rep       Date:  2016-12       Impact factor: 5.369

8.  Cross-Sectional Assessment of Achievement of Therapeutic Goals in a Canadian Multidisciplinary Clinic for Patients With Advanced Chronic Kidney Disease.

Authors:  Félix Rinfret; France Lambert; Joseph Tchetagni Youmbissi; Jean-François Arcand; Richard Turcot; Maral Alimardani Bessette; Solange Bourque; Vincent Moreau; Karine Tousignant; Diane Deschênes; Lyne Cloutier
Journal:  Can J Kidney Health Dis       Date:  2018-05-13

9.  Rapid weight loss with dietary salt restriction in hospitalized patients with chronic kidney disease.

Authors:  Yu Mihara; Hiroshi Kado; Isao Yokota; Yayoi Shiotsu; Kazuhiro Sonomura; Tetsuro Kusaba; Tsuguru Hatta; Satoaki Matoba; Keiichi Tamagaki
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

10.  Comorbidity Status and Annual Total Medical Expenditures in U.S. Hypertensive Adults.

Authors:  Chanhyun Park; Jing Fang; Nikki A Hawkins; Guijing Wang
Journal:  Am J Prev Med       Date:  2017-12       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.